– USA, MD – ValenzaBio, Inc., a biopharmaceutical company, today announced the appointment of Peter Greenleaf to its board of directors.
“Peter has an extensive track record in building and leading biopharmaceutical companies from early-stage through development and commercialization, and we very much welcome him to our board of directors. Peter’s depth of expertise will be instrumental to supporting the next phase of our company as it advances two clinical stage programs, an expanding pipeline of assets, and a maturing assessment of corporate and portfolio strategies,” said Board Chairman, Dr. John Doux.
About Peter Greenleaf
Mr. Greenleaf, a seasoned industry executive with nearly 30 years of experience leading successful life sciences companies, is currently the president, CEO, and member of the Board of Aurinia Pharmaceuticals, Inc., a fully integrated, publicly traded biopharmaceutical company advancing innovative treatments for autoimmune diseases.
“ValenzaBio is building a best-in-class suite of programs aimed at offering clear advantages to treating autoimmune and inflammatory conditions for patients, caregivers, and physicians,” said Peter Greenleaf. “With clinical readouts on the horizon and a compelling set of programs following closely behind, I’m excited to partner with this talented management team and the Board, as they work to bring meaningful new treatments to patients in need.”
Mr. Greenleaf has served the president, CEO, and member of the Board of Aurinia Pharmaceuticals, Inc., since April 2019. Prior to Aurinia, he held several CEO roles, including at Cerecor, Inc., Sucampo Pharmaceuticals, Inc., and Histogenics Corporation. Earlier, Mr. Greenleaf held positions at Medlmmune LLC, the global biologics arm of AstraZeneca, where he most recently served as president. Before that, he was SVP, commercial operations of MedImmune, responsible for its commercial, corporate development and strategy functions. Mr. Greenleaf has also held senior commercial roles at Centocor, Inc. (now Janssen Biotechnology, Johnson & Johnson) and Boehringer Mannheim (now Roche Holdings). Mr. Greenleaf earned his MBA from St. Joseph’s University and B.S. from Western Connecticut State University.
About ValenzaBio, Inc.
ValenzaBio is a privately held biopharmaceutical company developing safe and effective therapies for autoimmune and inflammatory diseases. The company is advancing a pipeline of differentiated monoclonal antibodies with best-in-class properties, targeting clinically validated mechanisms of action, to improve patient treatment options. VB421 is a potential best-in-class mAb targeting IGF-1R, which plays a central role in the pathogenesis of thyroid eye disease. In addition to VB421, ValenzaBio’s first program in clinic, VB119, continues to enroll trials in renal autoimmune indications actively. A third program, VB517 is expected to begin clinical trials in 2023. ValenzaBio is based in Bethesda, MD.
For more information: https://www.valenzabiotech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
